Video

Caleb Alexander, MD: Thoughts on the Opioid Epidemic

Author(s):

A pharmacoepidemiologist offers his comments on the ongoing opioid epidemic.

The ongoing opioid epidemic is a pervasive issue that healthcare providers are working to address and ultimately curb. However, solutions are not necessarily straightforward despite progress that has been made in this domain.

In a recent interview with HCPLive®, Caleb Alexander, MD, of Johns Hopkins Bloomberg School of Medicine, explained that such a crisis of this magnitude stems from complex factors. Rather than being attributed to a singular problem or issue, the epidemic has many different facets that contribute to its prevalence and severity.

“There are certainly still enormous concerns regarding the prevalence of opioid use and the risk-benefit balance of prescription opioids in many settings in which they are used,” Alexander said.

Of course, prescription medication is not only the domain of opioids that healthcare providers are worried about. He also indicated that the use of heroin and illicit fentanyl is still of considerable concern.

Nonetheless, Alexander considered the general embracing of the opioid epidemic as a concept to be a fortunate and positive step in the right direction. Furthermore, there are many efforts that have been undertaken to improve the identification and treatment of those with opioid use disorder.  

“This is an area where primary care can especially play an important role,” Alexander concluded.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.